UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 22, 2009
INVERNESS MEDICAL INNOVATIONS, INC.
(Exact name of registrant as specified in charter)
| |
|
|
|
|
| Delaware
|
|
1-16789
|
|
04-3565120 |
|
|
|
|
|
|
| (State or Other
|
|
(Commission File Number)
|
|
(IRS Employer |
| Jurisdiction
|
|
|
|
Identification No.) |
| of Incorporation) |
|
|
|
|
51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453
(Address of Principal Executive Offices) (Zip Code)
(781) 647-3900
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Inverness Medical Innovations, Inc. (the “Company”) is filing this Current Report on Form
8-K to provide the legal opinion of Jay McNamara, Esq., the Company’s Senior Counsel, Corporate &
Finance, relating to the Company’s prospectus supplement filed with the SEC on December 22, 2009
(File No. 333-158542).
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
5.1
|
|
Opinion of Jay McNamara, Esq., Senior Counsel, Corporate & Finance, of the Company |
|
|
|
23.1
|
|
Consent of Jay McNamara, Esq., Senior Counsel, Corporate & Finance, of the
Company (included in Exhibit 5.1) |